Kotra Industries Bhd

Kotra Industries Bhd maintains a strong liquidity position, with a current ratio of 2.9, indicating the company can cover its short-term liabilities more than two times over. However, the company reported negative free cash flow of MYR -30.23 million, primarily due to capital expenditures of MYR -35.98 million, which exceeded operating cash flow of MYR 45.91 million. The company's debt-to-equity ratio is effectively zero, as long-term debt is minimal at MYR 326,000, suggesting a conservative capital structure. Profitability metrics for Kotra Industries Bhd show a return on equity (ROE) of 2.6% and a return on assets (ROA) of 2.17%. These figures are below the industry median for pharmaceutical companies, which typically report ROE and ROA in the 5-8% range. The company's net income of MYR 6.83 million on revenue of MYR 55.88 million results in a net margin of 12.2%, which is in line with the industry average. Geographically, Kotra Industries Bhd's revenue is concentrated in Malaysia, with no disclosed international operations. The company's business is primarily driven by domestic demand for pharmaceutical products, which exposes it to local economic conditions and regulatory changes. The company operates in a single business segment, focusing on pharmaceuticals, with no material diversification into other healthcare subsectors. Looking ahead, Kotra Industries Bhd is projected to maintain stable revenue growth, with analysts forecasting a mean price target of MYR 4.90 per share. The company's operating income of MYR 13.91 million and net income of MYR 6.83 million suggest a solid earnings base, but the negative free cash flow indicates ongoing investment in capital expenditures. The company's revenue has remained relatively stable in recent periods, with no significant year-over-year growth reported. Risk factors for Kotra Industries Bhd include liquidity concerns, as the company has negative net cash after subtracting total debt. While the company's debt levels are low, the negative free cash flow could limit its ability to fund operations or pursue growth opportunities without external financing. The risk of dilution is currently low, as the number of shares outstanding has not changed between basic and diluted shares. However, the company's capital expenditures may require additional financing in the future, which could lead to share dilution or increased debt. Recent events for Kotra Industries Bhd include the publication of its latest financial results, which show a stable revenue base and moderate profitability. The company has not disclosed any major strategic initiatives or new product launches in recent filings. Analysts have issued a single "buy" recommendation, with no strong buy or hold ratings, indicating a cautious outlook for the stock.